Purple Biotech (PPBT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PPBT Purple Biotech

Watchlist

2.190
-0.350-13.78%

Close Nov 22 16:00 ET

2.310
+0.120+5.48%

Post 20:02 ET

3.43MMarket Cap0.29P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target
BenzingaNov 15 14:44 ET
Promising Interim Results Propel Purple Biotech's Buy Rating Amid Phase 2 Success and Strategic Advancements
TipRanksNov 15 12:15 ET · Ratings
Purple Biotech's Promising Trials and Financial Update
TipRanksNov 15 07:29 ET
Purple Biotech GAAP EPS of -$0.39
Seeking AlphaNov 15 07:10 ET
Purple Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
SECNov 15 07:08 ET · Announcements
Express News | Purple Biotech Ltd: Qtrly Loss per Ads $4.57
ReutersNov 15 07:03 ET

Comments

Stock_Drift

Nov 15 06:06

$Purple Biotech (PPBT.US)$

Trytosaveabit

Nov 4 06:52

Update

$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results

Trytosaveabit

Oct 25 06:50

Update

$Purple Biotech (PPBT.US)$ Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants

Lead tribody IM1240 data demonstrated...